Pathology and Oncology Research (Jul 2022)

Molecular Landscape of ERBB2 Alterations in 14,956 Solid Tumors

  • Hao Wang,
  • Ji Miao,
  • Yazhou Wen,
  • Xihua Xia,
  • Yanan Chen,
  • Mengli Huang,
  • Shiqing Chen,
  • Zhengyi Zhao,
  • Yuzi Zhang,
  • Chunzhu Chen,
  • Xinhua Zhu

DOI
https://doi.org/10.3389/pore.2022.1610360
Journal volume & issue
Vol. 28

Abstract

Read online

ERBB2 abnormalities frequently occur and serve as rationale therapeutic targets in cancer. In this study, clinical and next-generation sequencing data from 14,956 patients across more than 20 tumor types were collected. A total of 406 (2.7%) patients were identified with ERBB2 amplifications, and 303 (2.0%) patients with pathogenic somatic ERBB2 mutations. ERBB2 amplifications fell most frequently in breast (15.9%) and stomach (8.3%) cancers. Somatic ERBB2 SNVs/indels occurred most common in bladder/urinary tract (7.3%) and intestine (6.1%) cancers. The top mutated ERBB2 SNVs/indels were p.Y772_A775dup (25.5%) and p.S310F/Y (19.9%). Significantly higher rates of ERBB2 SNV/indels were found in women compared to men (2.8% vs. 1.5%, p < 0.0001). CDK12 was the most common co-amplification gene with ERBB2 in cancers with a high frequency of ERBB2 amplifications. Patients with ERBB2 amplifications or mutations had higher TMB compared with patients with non-ERBB2 alterations. The study provided the landscape of ERBB2 alterations across a variety of solid tumors that may benefit from anti-HER2 agents.

Keywords